In 1998, interleukin-2 (IL-2), a T-cell growth factor that aids in immune regulation and T-cell proliferation, became the second antitumor cytokine approved by the FDA when it was approved in the treatment of metastatic melanoma and renal cell carcinoma (Kirkwood et al., 2012). This evidence concerns the gene IL2 and metastatic melanoma.